The stock of AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) closed at $2.98 gaining 1.02% in yesterday’s trading session. Ficlatuzumab and FOTIVDA® (tivozanib) are two programs that this company is focusing on at the moment. AVEO has today unveiled the clinical updates of these two.
The lead researcher revealed that they were compelled to put long hours in the whole process and that is why they have managed to give the updates earlier than was expected.
The president and chief executive officer of AVEO, Michael Bailey opined, “We continue to build strong momentum in our oncology programs, including progress with our lead program, tivozanib, and the advancement of our other oncology programs, including ficlatuzumab and AV-203. With approval of tivozanib and commercial sales underway in Europe, we are squarely focused on the next two pillars of our tivozanib strategy.”
Bailey was referring to the additional immunotherapy combination studies and the potential for U.S. registration. The passage of time is witnessing the strategies unfold and if everything goes according to plan it is expected that 2018 will be a year of great transformation.
This company will be initiating two ficlatuzumab investigator-sponsored studies with the aim of developing a wide range of working solutions for the various struggling patients around the globe. One thing about AVEO is the fact that it has always been keen on taking advantage of the various technological advancements sweeping across the world. It usually leverages on them and that is the reason it has succeeded to make a name for itself despite the ever shifting market dynamics around the globe.
At this point in time, AVEO has succeeded in enrolling 21 patients. One patient is still undergoing screening but the company says that it just started on the right foot. One of the officials working with the company in a recent interview outlined that they were determined and won’t at any point stop in their quest to make the world a better place by coming up with solutions that will help enhance lives. He attested to the fact that it was a costly exercise coming up with top quality products.